Literature DB >> 7382823

Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis.

C H Chesnut, D J Baylink, K Sisom, W B Nelp, B A Roos.   

Abstract

Calcitonin (CT) deficiency has been suggested as an etiologic factor in postmenopausal osteoporosis (PM-OP). Basal immunoreactive calcitonin (iCT) was measured with a sensitive radioimmunoassay (RIA) in 62 PM-OP women with compression fractures (CF) and in 28 normal age-matched women. Mean iCT values in the two groups were not significantly different (43.5 and 45.1 pg/ml, p greater than 0.10). In the 62 PM-OP females, no significant correlation was noted between basal plasma iCT levels and (1) age; (2) severity of disease as assessed by number of CF; (3) serum calcium, phosphorus, alkaline phosphatase, and immunoreactive parathyroid hormone; and (4) total bone mass as assessed by neutron activation analysis determinations of total body calcium (TBC). In 20 PM-OP patients treated for 24 mo with 100 Medical Research Council (MRC) units daily of synthetic salmon CT, no correlation was observed between basal plasma iCT and response of bone mass (TBC) to therapy. These data suggest that basal CT is not decreased in women with PM-OP, and that the level of circulating CT does not influence therapeutic changes in bone mass during CT therapy. CT is probably not a major etiologic or pathogenetic factor in PM-OP.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7382823     DOI: 10.1016/0026-0495(80)90082-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Bone mass and mineral metabolism in Klinefelter's syndrome.

Authors:  G Luisetto; I Mastrogiacomo; G Bonanni; G Pozzan; S Botteon; L Tizian; P Galuppo
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

3.  Absence of evidence for a role of calcitonin in the etiology of femoral neck fracture.

Authors:  T R Beringer; J Ardill; H M Taggart
Journal:  Calcif Tissue Int       Date:  1986-11       Impact factor: 4.333

4.  Calcitonin, estradiol, and hydroxyproline as parameters in the early diagnosis of involutional osteoporosis. The importance of the "second calcitonin phenomenon".

Authors:  L Ferrández; M Martín; M Fernández
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

5.  Calcitonin secretion rate in elderly normal subjects.

Authors:  M Pedrazzoni; G Ciotti; L Davoli; G Pioli; G Girasole; T Santini; M Michelini; P P Vescovi; M Passeri
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

6.  Calcitonin metabolism in senile (type II) osteoporosis.

Authors:  J Y Reginster; R Deroisy; M Bruwier; P Franchimont
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

Review 7.  [Calcitonin and osteoporosis--a critical review of the literature 1980-1989].

Authors:  H G Haas; B M Liebrich; W Schaffner
Journal:  Klin Wochenschr       Date:  1990-04-02

Review 8.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

9.  Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.

Authors:  J Y Reginster; R Deroisy; A Albert; D Denis; M P Lecart; J Collette; P Franchimont
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 alpha-hydroxylase reserve in postmenopausal osteoporosis.

Authors:  R Civitelli; D Agnusdei; P Nardi; F Zacchei; L V Avioli; C Gennari
Journal:  Calcif Tissue Int       Date:  1988-02       Impact factor: 4.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.